Procurement of lateral flow (LFA) strips for the rapid HIV nucleic acid diagnostic test

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

CDC OFFICE OF ACQUISITION SERVICES

Contract Value

Not provided

Codes & Classification
Solicitation Number

75D30126Q79099

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

AJ11

Additional Details
Set Aside

NONE

Place of Performance

Atlanta, Georgia, UNITED STATES

SourceSAM
Documents4
The Centers for Disease Control and Prevention (CDC), under the Department of Health and Human Services, has issued a combined synopsis/solicitation for the procurement of lateral flow assay (LFA) strips intended for use in rapid HIV nucleic acid diagnostic testing. This procurement is being conducted as a commercial item acquisition in accordance with Federal Acquisition Regulation (FAR) Subpart 12.202, and is solicited under Request for Quote (RFQ) number 75D30126Q79099. The primary objective of this procurement is to secure a reliable supply of LFA strips that will support the CDC’s ongoing efforts in HIV research and diagnostics. The LFA strips are critical components for rapid nucleic acid testing, which plays a vital role in early detection and management of HIV. The intended outcome is to enhance the CDC’s capacity to conduct timely and accurate HIV diagnostics, thereby supporting public health initiatives and research activities. The scope of the contract encompasses the delivery of commercial-grade LFA strips that meet the CDC’s technical and quality requirements, as detailed in the attached RFQ. Offerors are expected to provide comprehensive proposals that address all requirements, including product specifications, pricing, and delivery timelines. The period of performance for this contract is set from August 15, 2026, to January 15, 2027, with all deliverables to be provided to the CDC’s facility at 1600 Clifton Road, Building 17, Atlanta, GA 30329-4018. Key requirements for this solicitation include: - Provision of lateral flow assay strips suitable for rapid HIV nucleic acid diagnostic testing. - Compliance with all applicable commercial product standards and CDC specifications as outlined in the RFQ. - Adherence to the firm-fixed-price contract structure, ensuring cost predictability and accountability. - Registration in the System for Award Management (SAM) at the time of quote submission. The procurement is classified under NAICS code 541714, “Research and Development in Biotechnology (except Nanobiotechnology),” and Product Service Code AJ11. There are no set-aside restrictions for this solicitation; it is open to all qualified vendors. The CDC Office of Acquisition Services is the contracting entity responsible for this procurement. Interested offerors should note the following procedural details: - All questions regarding the solicitation must be submitted by close of business on Monday, July 23, 2026. - Quotes must be submitted electronically by 3:00 P.M. Eastern Standard Time on Friday, July 29, 2026. No telephonic quotes will be accepted. - The quote format is at the discretion of the offeror, but must comply with the instructions and evaluation criteria specified in the RFQ. - Applicable FAR clauses and provisions include 52.212-1 (Instructions to Offerors—Commercial Products and Commercial Services) and 52.212-4 (Contract Terms and Conditions—Commercial Products and Commercial Services). For further information or to submit questions and proposals, offerors should contact Eugene L. Gutierrez Jr., Contract Specialist, at [email protected] or 770-488-0192. Secondary contact is Liubov Kriel at [email protected] or 770-488-2856. This opportunity remains active and all relevant solicitation documents, including the RFQ and associated clauses, are available via the official SAM.gov listing at https://sam.gov/opp/21251008f2504613b9bf2120fd239106/view. Contractors with expertise in biotechnology research and diagnostic assay production are encouraged to review the full solicitation and consider submitting a proposal if their capabilities align with the CDC’s requirements for this critical public health initiative.